Opportunity Webinar Harnessing Anti-Cytomegalovirus Immunity for Local Immunotherapy against Solid Tumors

December 14, 2022 | 11:00 AM – 12:00 PM

Add to Outlook Calendar

If you missed our December 14th Technology Opportunity Webinar, you can request the recording. Attendees heard from Deputy Chief of the NCI CCR Laboratory of Cellular Oncology, John Schiller, Ph.D. about a new immunotherapy method targeting solid tumors. This invention involves the injection of cytomegalovirus- (CMV) derived T cell minimal peptide epitopes into a solid tumor, disrupting the tumor microenvironment and allowing CD4+ and CD8+ T cells to kill the tumor cells and the generation of T cells to tumor-restricted antigens. The tumor antigen-agnostic nature of this approach makes it applicable across a broad range of solid tumors, regardless of origin. The results of his work show that CMV-derived peptide epitopes, delivered intratumorally into mice with chronic mouse CMV infections, act as cytotoxic and immunotherapeutic agents to promote immediate tumor control and long-term antitumor immunity. This technology can be used as a stand-alone therapy. Please reach out to Joseph.Conrad@nih.gov to request the recording, or if you have interest in learning about co-development and/or licensing opportunities for this technology.